Thanks Denial.
I will be in touch with Paradigm about the trial and some other questions I have.
From my read the initial phase 3 (oa 11) did not meet primary end points but their extension study oa o7 did meet its primary "objective" and did show structural benefit over placebo..
It seems we are obviously way more advanced and our target of KL 3 and 4 is different to where their drug shows most benefit KL2.
I assume they would also need to start a whole new FDA aproved phase 3. So it kooks like we are good...
I also noticed another early trial for hand and finger joint OA with another repurposed drug called Talarozole. Different specific indication and early days but worth noting
https://www.medicalnewstoday.com/articles/new-repurposed-drug-talarozole-hand-osteoarthritis
Thanks Denial.I will be in touch with Paradigm about the trial...
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 9445 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |